CWBR Cohbar Inc

CohBar’s CEO to Participate on the Emerging Companies Panel at the Targeting Metabesity Conference

CohBar’s CEO to Participate on the Emerging Companies Panel at the Targeting Metabesity Conference
EN
08/10/2020

Underlying

CWBRCohbar Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cohbar Inc

 PRESS RELEASE
Free
CWBR COHBAR INC

CohBar Reports Second Quarter 2023 Financial Results

CohBar Reports Second Quarter 2023 Financial Results MENLO PARK, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) today reported its financial results and highlights for the second quarter ended June 30, 2023. Second Quarter 2023 Summary and Financial Results Entered into Definitive Merger Agreement with Morphogenesis: In May 2023, CohBar announced that the company entered into a definitive merger agreement with a privately held biotechnology company, Morphogenesis, Inc. (“Morphogenesis”), for an all-stock transaction to advance a late-stage oncology pipeline. The c...

August 14, 2023 1 EN
 PRESS RELEASE
Free
CWBR COHBAR INC

Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Ph...

Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC) IFx-Hu2.0 demonstrated to have a promising safety profile at all 3 dose schedules tested 5 of 7 (71%) of patients achieved durable systemic anti-tumor responses following IFx-Hu2.0 therapy and rechallenge with an immune checkpoint inhibitor (ICI) in patients who exhibited primary resistance to ICIs Translational biomarker data underscores ...

June 5, 2023 1 EN
 PRESS RELEASE
Free
CWBR COHBAR INC

Morphogenesis, Inc. and CohBar, Inc. Announce Acceptance of Abstract f...

Morphogenesis, Inc. and CohBar, Inc. Announce Acceptance of Abstract for Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting TAMPA, Fla. and MENLO PARK, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- Morphogenesis, Inc. (“Morphogenesis”), a privately-held Phase 2/3 clinical-stage biotechnology company developing novel personalized cancer vaccines and tumor microenvironment modulators to overcome resistance to current immunotherapies, and CohBar, Inc. (NASDAQ: CWBR) (“CohBar”), today announced that Morphogenesis’ abstract has been accepted for poster prese...

May 30, 2023 1 EN
 PRESS RELEASE
Free
CWBR COHBAR INC

CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agre...

CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy Combined company will operate under the name “TuHURA Biosciences, Inc.” and advance a personalized cancer vaccine platform and preclinical tumor microenvironment modulatorsLead asset, IFx-Hu2.0, expected to enter Phase 2/3 registration trial as first-line treatment for Merkel Cell Carcinoma in early 2024$15 million PIPE financing to close concurrent with the closing of the proposed merge...

May 23, 2023 1 EN
 PRESS RELEASE
Free
CWBR COHBAR INC

CohBar Reports Third Quarter 2022 Financial Results and Highlights Rec...

CohBar Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress Conference call and webcast today at 5:00 p.m. ET, November 8, 2022 MENLO PARK, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today reported its financial results for the third quarter ended September 30, 2022 and highlighted recent corporate progress. “I’m plea...

November 8, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch